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Background : Angiotensin-converting enzyme inhibitors (ACEI) should be titrated to the optimal dose for 
adequate inhibition of the Renin-Angiotensin-Aldosterone system (RAAS). The up-titration of ACEI to the optimal 
doses during in-hospital treatment is challenging. 
Objectives : This study aimed to investigate whether the use of optimal dose of ACEI during in-hospital treatment 
could give more benefit to the outcome of heart failure (HF) patients.
Methods : We involved 171 HF patients in this prospective cohort study. 29 and 142 HF patients were treated with 
optimal dose and suboptimal dose of ACEI during in-hospital treatment, respectively. The primary endpoint was 
in-hospital and 30 days post-discharge mortality. The secondary endpoint was 30 days post-discharge rehospital-
ization due to worsening of HF.
Results: Only 17% of HF patients treated with optimal dose of ACEI during in-hospital treatment. In-hospital 
mortality in optimal dose of ACEI group was lower than in suboptimal dose of ACEI group (0% vs. 19.7%; p = 
0.009). The 30 days post-discharge mortality (0% vs 2.7%; p = 0.375) and rehospitalization (6.9% vs 16.7%; p 
= 0.184) between both groups were not significantly different. 
Conclusion: The use of optimal dose of ACEI during in-hospital treatment reduced in-hospital mortality in HF 
patients.
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 HF patients suffered from decreased quality of life, intoler-
ance to physical activity, frequent hospital admission, and increased 
mortality.1,2 The latest data revealed that one-year all-cause mortality 
rates for ambulatory and hospitalized HF patients were 7% and 17%, 
respectively.2 Rehospitalization rates of HF increased from 10-19% at 
two weeks to 50% at three months after hospital discharge.3 High 
rehospitalization rate in HF patients was caused by inadequate 
therapeutic strategies, poor patient comprehension about their 
conditions, and also low compliance with the treatment regimens.3–5 
 The use of neurohormonal antagonists, such as ACEI, was 
the backbone of HF treatment strategies.6 Chronic therapy with ACEI 
had been proven to effectively improve left ventricle (LV) function, 
improve exercise capacity, reduce hospitalization, and, most important-
ly, improve survival in HF patients.7–9 ACEI should be titrated to the 
optimal dose to achieve adequate inhibition of the RAAS.1,2 In daily 
clinical practice, the up-titration of ACEI to the optimal doses during 
in-hospital treatment is challenging because of its side effects or the 
presence of several comorbidities. Renal dysfunction was a major 
limitation of ACEI up-titration, in addition to hypotension, electrolyte 
disturbances, and low compliance levels.10,11 However, few studies have 
compared optimal vs. suboptimal of ACEI on mortality and morbidity 
for HF patients.10,12,13 This study aimed to investigate whether the use of 
optimal dose of ACEI during in-hospital treatment could give more 
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 It was a prospective cohort study conducted at Saiful Anwar 
General Hospital Malang from October 1st, 2016, until August 31st, 
2017. The investigation conformed with the principles outlined in the 
Declaration of Helsinki and was approved by the Ethical Committee of 
Saiful Anwar General Hospital. 
2.2. Study population
 All patients over 18 years admitted to Saiful Anwar General 
Hospital with an initial diagnosis of HF were screened. HF diagnosis 
was established by a cardiologist based on the presence of all of the 
following variables: signs and symptoms compatible with HF, cardio-
megaly and/or pulmonary congestion assessed using chest X-ray, and 
also LV dysfunction assessed using echocardiography.14 Informed 
consent was obtained from all HF patients who participated in this 
study. All patient’s data such as demographic data, cardiovascular risk 
factors, medical history, symptoms, signs, laboratory examination, 
electrocardiography, chest X-ray, echocardiography, exercise stress 
test, Holter monitor, and also the treatment regimens were registered. 
Patients were not treated with or contraindicated to ACEI were exclud-
ed (See Figure 1). 
2.3. Study groups
 Patients were divided into two groups according to the 
treatment regimens during in-hospital treatment. Patients in optimal 
dose of ACEI group were treated with optimal dose of ACEI according 
to the 2016 European Society of Cardiology (ESC) guideline for HF 
(captopril 50 mg three times daily, ramipril 10 mg daily, or lisinopril 20 
mg daily) during in-hospital treatment.2 In suboptimal dose of ACEI 
group, patients were treated with suboptimal dose of ACEI during 
in-hospital treatment (See Figure 1). 
2.4. Follow up
 The follow-up period was 30 days following hospital 
discharge. At the end of the follow-up period, information regarding 
mortality, rehospitalization, symptoms of HF, New York Heart Associa-
tion (NYHA) functional class, current treatment regimens, and compli-
ance to the treatment regimens was obtained from patients or their 
family by phone call. 
Figure 1. A flowchart of patients selection in this study
2.5. Study endpoints
 The primary endpoint included in-hospital and 30 days 
post-discharge mortality. The secondary endpoint was 30 days post-dis-
charge rehospitalization due to worsening of HF.
2.6. Statistical analysis
 Categorical variables are presented as frequencies and 
percentages. The comparison between 2 categorical variables was 
tested using the Chi-square test or Fisher's test. The Spearman correla-
tion test was used to assess the correlation between the two variables. 
P-value ≤ 0.05 was considered statistically significant. All statistical 
analyses were conducted using IBM SPSS Statistics 21.
3. Results
3.1. Patients basic characteristics
 The patient’s average age was 58 ± 12 years, and 61.4% of 
them were male. Among the 300 HF patients registered, 129 (43%) 
patients were excluded because they were not treated with ACEI or 
contraindicated with ACEI. Of 171 patients who involved in this study, 
29 (17%) patients and 142 (83%) patients were treated with optimal 
doses and suboptimal dose of ACEI during in-hospital treatment, 
respectively (See Figure 1). There were no significant differences 
between both groups in age, gender, ethnic, level of education, occupa-
tion, marital status, history of HF, the main cause of HF, smoking status, 
atrial fibrillation, diabetes mellitus (DM), physical activity, history of 
myocardial infarction (MI) or angina, history of percutaneous coronary 
intervention (PCI), history of transient ischemic attack (TIA), history of 
chronic kidney disease (CKD), history of impaired liver function, history 
of HF hospitalization, history of chronic obstructive pulmonary disease 
(COPD), history of hypertension, NYHA functional class, history of 
medication (Angiotensin receptor blocker (ARB), beta-blockers, 
aldosterone antagonist, and diuretic). Both groups got similar concomi-
tant treatments with beta-blockers, aldosterone antagonists, and diuret-
ics (See Table 1). We also noted the reasons that optimal dose of ACEI 
could not be achieved during in-hospital treatment. It was because of 
shock or hypotension in 37 patients (26%), renal azotemia in 31 
patients (22%), hyperkalemia in 4 patients (2.8%), and unclear reasons 
in 70 patients (49.2%).
3.1. Clinical outcome
In-hospital mortality 
 In optimal dose of ACEI group, no patient passed away 
during in-hospital treatment (0%), while in suboptimal dose of ACEI 
group, 28 patients passed away during in-hospital treatment (19.7%). 
The causes of death suboptimal dose of ACEI group were cardiogenic 
shock in 9 patients (32.1%), sudden cardiac death in 3 patients 
(10.7%), ventricular fibrillation in 3 patients (10.7%), and non-cardiac 
cause (respiratory failure, pneumonia, sepsis, and acute respiratory 
distress syndrome) 13 patients (46.5 %). The data analysis revealed 
that in-hospital mortality in optimal dose of ACEI group was lower than 
in suboptimal dose of ACEI group (0% vs. 19.7%; p = 0.009). It was 
also supported by the Spearman’s correlation test (correlation 
coefficient value = -0.200; p = 0.009). It could be concluded that there 
was a significant correlation between optimal dose of ACEI and in-hos-
pital mortality (See Table 2). 
30 days post-discharge mortality
 During the follow-up period of 30 days following hospital 
discharge, three patients in suboptimal dose of ACEI group were passed 
away. Two patients passed away because of cardiogenic shock, while 
one patient passed away because of sudden cardiac death. Data analysis 
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The 300 HF patients registered
and signed informed consent
171 HF included included in this
prospective cohort study
29 patients were treated with
optimal dose of ACEI
142 patients were treated with
suboptimal dose of ACEI
129 patients were excluded 
because of:
• not treated with ACEI 
• contraindicated with ACEI
• In-hospital post-discharge mortality
• 30 days post-discharge mortality
• 30 days post-discharge rehospitalization due to worsening of HF
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revealed no significant difference in 30 days post-discharge mortality 
between both groups (0% vs. 2.7%; p = 0.375) (See Table 3). 
30 days post-discharge rehospitalization due to worsening of HF
 In optimal doses of ACEI group, 30 days post-discharge 
rehospitalization due to worsening of HF occurred in 2 patients (6.9%). 
The precipitating factors of rehospitalization were poor compliance  
with the treatment regimen and infection. While in suboptimal doses of 
ACEI group, 30 days post-discharge rehospitalization due to worsening 
of HF occurred in 19 patients (16.7%). The precipitating factors of 
rehospitalization were inadequate treatment regimens in 16 patients 
(84%) and poor compliance with the treatment regimen in 3 patients 
(16%). Data analysis revealed no significant difference in 30 days 
post-discharge rehospitalization between both groups (6.9% vs. 16.7%; 
p = 0.184) (See Table 4). 
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Table 1. Patient’s basic characteristic
Demographic 
characteristic  Category  
 
Optimal  dose of ACEI 
(n = 29)  
 
Su boptimal  dose of ACEI  
(n = 142)  p-value  
Frequency  % Frequency  % 
Sex  
Female  9 13.6%  57  86.4%  
0.359  
Male  20  19%  85  81%  
Age (years)  
<60  19  20.2%  75  79.8%  
0.317  
60 -69  8 16.7%  40  83.3%  
70 -79  1 4.2%  23  95. 8%  
>80  1 20%  4 80%  
Ethnic  
Java  28  16.6%  141  83.4%  
0.077  Chinese  0 0%  1 100%  
Arabian  1 100%  0 0%  
Education  
No school  2 16.7%  10  83.3%  
0.965  
Not completed primary school  1 25%  3 75%  
Completed primary school  7 15.9%  37  84.1%  
Completed junior high school  8 21.1%  30  78.9%  
Completed senior high school  10  15.6%  54  84.4%  
Bachelor  1 11.1%  8 88.9%  
Occupation  
Unemployed  7 17.1%  34  82.9%  
0.482  
Student  0 0%  2 100%  
Housewife  6 28.6%  15  71.4%  
Government employees  0 0%  8 100%  
Retired  1 7.7%  12  92.3%  
Entrepreneur  12  19%  51  81%  
Farmer  3 18.8%  13  81.2%  
Labour  0 0%  7 100%  
Marital status  
Single  0 0%  5 100%  
0.479  Married  28  17.9%  128  82.1%  
Divorce/widow  1 10%  9 90%  
History of HF  
No  8 17.8%  37  82.2%  
0.865  
Yes  21  16.7%  105  83.3%  
Main cause  
IHD  documented by CAG  5 23.8%  16  76.2%  
0.312  
IHD  not documented by  CAG  15  16.1%  78  83.9%  
Dilated cardiomyopathy  5 33.3%  10  66.7%  
Valve disease  0 0%  12  100%  
Hypertension  3 13%  20  87%  
Pulmonary hypertension  1 25%  3 75%  
Others  0 0%  3 100%  
Never  14  16.5%  71  83.5%  
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Note; ACEI = angiotensin-converting enzyme inhibitor; ARB = angiotensin receptor blocker; CAG = coronary angiogram; CKD = chronic kidney disease; COPD = 
chronic obstructive pulmonary disease; HF = heart failure; IHD = ischemic heart disease MI = myocardial infarction; NYHA = New York Heart Association; PCI = 
percutaneous coronary intervention; TIA = transient ischemic attack
Atrial fibrilation  
Never  26  18.4%  115  81.6%  
0.463  
Permanent  2 14.3%  12  85.7%  
Persistent  1 20%  4 80%  
Paroxysmal  0 0%  11  100%  
Diabetes melitus  
Yes  9 20%  36  80%  
0.527  
No  20  15.9%  106  84.1%  
Physical activity  
Mild  8 14.8%  46  85.2%  
0.194  Moderate  19  16.8%  94  83.2%  
Heavy  2 50%  2 50%  
History of MI /angina  
No  18  14.9%  103  85.1%  
0.259  
Yes  11  22%  39  78%  
History of PCI  
No  25  16 % 131  84%  
0.294  
Yes  4 26.7%  11  73.3%  
History of TIA /stroke  
No  29  18.4%  132  81.6%  
0.141  
Yes  0 0%  10  100%  
History of CKD  
No  29  17.4%  138  82.6%  
0.360  
Yes  0 0%  4 100%  
History of impaired 
liver function  
No  28  16.8%  139  83.2%  
0.665  
Yes  1 25%  3 75%  
History of HF  
hospitalization  
No  20  20.6%  77  79.4%  
0.144  
Yes  9 12.2%  65  87.8%  
History of COPD  
No  28  17%  137  83%  
0.984  
Yes  1 16.7%  5 83.3%  
History of 
hypertension  
No  19  17.8%  88  82.2%  
0.719  
Yes  10  15.6%  54  84.4%  
NYHA  functional class  
I 1 50%  1 50%  
0.397  
II 9 20%  36  80%  
III  8 12.3%  57  87.7%  
IV 11  18.6%  48  81.4%  
Prior ARB  
No  28  17.9%  128  82.1%  
0.266  
Yes  1 6.7%  14  93.3%  
Prior blocker -bloker  
No  22  17.1%  107  82.9%  
0.954  
Yes  7 16.7%  35  83.3%  
Prior aldosterone 
antagonist  
No  25  17.4%  119  82.6%  
0.746  
Yes  4 57.1%  3 42.9%  
Prior diuretic  
No  23  18.3%  103  81.7%  
0.450  
Yes  6 13.3%  39  86.7%  
Current beta -bloker  
No  8 11.4%  62  88.6%  
0.109  
Yes  21  20.8%  80  79.2%  
Current aldosterone
antagonist  
No  11  13.4%  71  86.6%  
0.236  
Yes  18  20.2%  71  79.8%  
Current diuretic  
No  13  13.7%  82  86.3%  
0.202  
Yes  16  21.1%  60  78.9%  
 
Smoking status  0.748  Current  4 13.3%  26  86.7%  
Former  11  19.6%  45  80.4%  
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4. Discussion
 The benefit of optimal dose ACEI in HF patients is the 
reduction of mortality and rehospitalization. According to the current 
guideline for HF, the administration of ACEI gives more benefit for (1) 
all HF patients with left ventricular ejection fraction (LVEF) <40%; (2) 
HF patients with NYHA functional class II-IV; or (3) HF patients with 
asymptomatic LV dysfunction (NYHA functional class I).2 The absolute 
contraindications of ACEI are (1) history of angioedema; (2) known 
bilateral renal artery stenosis; (3) pregnancy or risk of pregnancy; and 
(4) known allergic reaction or other adverse reaction.2,15 Cautions for 
ACEI administration are (1) significant hyperkalemia (potassium level 
> 5 mmol/L); (2) significant renal dysfunction (creatinine level > 2.5 
gr/dL or eGFR <30 mL/min/1.73 m2); and (3) symptomatic or severe 
asymptomatic hypotension (systolic blood pressure <90 mmHg).2 
Among 300 HF involved in this study, 171 (57%) patients were treated 
with ACEI. It was lower than the report from the previous real-world 
studies which revealed the use of ACEI for HF ranging from 70.1% to 
81.6%.16–18 The possible explanations of this result were: (1) the 
previous studies were conducted in the out-patient clinical setting; (2) 
most of the patient involved in the previous studies were in more stable 
clinical condition; and (3) our study was conducted in the in-hospital 
setting in which most of the patients involved in this study were on 
relative unstable clinical condition with several comorbidities. Never-
theless, our study provided data about the use of ACEI for HF during 
in-hospital treatment.
 Among 171 patients treated with ACEI, only 29 patients 
(17%) received an optimal dose of ACEI during in-hospital treatment. It 
was lower than the report from the previous real-world studies which 
revealed the use of optimal dose of ACEI for HF ranging from 37.5% to 
65%.16–18 The possible explanations of this result were: (1) the previous 
studies were conducted in the out-patient clinical setting; (2) most of 
the patient involved in the previous studies were in more stable   
clinical condition; and (3) our study was conducted in the in-hospital 
setting in which most of the patients involved in this study were on 
relative unstable clinical condition with several comorbidities; (4) the 
up-titration of ACEI to the optimal dose could be conducted in the 
out-hospital setting; and (5) The guidelines did not give a specific 
recommendation to up-titrate ACEI to the optimal dose during in-hospi-
tal treatment.2,19 In this study, the limitation of the up-titration of ACEI 
to the optimal dose during in-hospital treatment was caused by shock or 
hypotension in 37 patients (26%), renal azotemia in 31 patients (22%), 
hyperkalemia at four patients (2.8%), and unclear reasons in 70 
patients (49.2%).
 Our study revealed that the administration of optimal dose of 
ACEI during in-hospital treatment could reduce 19.7% of in-hospital 
mortality in HF patients. The higher mortality in suboptimal doses of 
ACEI group could be caused by suboptimal doses of ACEI itself or the 
presence of several comorbidities such as hypotension, hyperkalemia, 
or azotemia that prevent the administration of optimal dose of ACEI. 
According to the results of previous studies, hypotension (low systolic 
blood pressure and diastolic blood pressure), hyperkalemia, or 
azotemia increased mortality in HF patients independently.17–20 Accord-
ing to our knowledge, there were no RCTs or prospective studies 
investigating the benefit of optimal dose of ACEI during in-hospital 
treatment for HF patients. Our study provided data about the benefit of 
optimal dose of ACEI for HF patients in reducing mortality during 
in-hospital treatment.
 Our study also revealed no significant difference in 30 days 
post-discharge mortality and rehospitalization between HF patients 
who received optimal and suboptimal doses of ACEI. There are two 
RCTs compared low dose and high dose of ACEI for HF patients.12,13 
Study of Pacher et al. compared to low dose enalapril (5 mg twice daily) 
and high dose enalapril (20 mg twice daily). After 48 weeks of the 
follow-up period, the functional capacity assessed by NYHA functional
12
 Categories  
Optimal dose of 
ACEI  
(n = 29)  
Suboptimal  dose of  
ACEI  









Frequency  % Frequency  % 
In -hospital mortality  
 
Yes  0  0%  28  19,7% 6.838  0.009  -0.200  0.009  No  29  100%  114 80.3% 
Note; ACEI = angiotensin-converting enzyme inhibitor; HF = heart failure
Table 2. In-hospital mortality
 Categories  
Optimal dose of 
ACEI  
(n = 29)  
Suboptimal  dose of  
ACEI  









Frequency  % Frequency  % 
Table 4. 30 days rehospitalization due to worsening of HF
30 days post -discharge 
rehospitalization due 
to worsening of HF  
Yes  2  6.9%  19  16.7%  
1.761  0.184  -0.111  0.187  No  27  93.1% 95 83.3% 
Note; ACEI = angiotensin-converting enzyme inhibitor; HF = heart failure
30 days post - discharge 
mortality  
Yes  0  0%  3  2.7% 0.787  0.375  -0.074  0.379  No  29  100% 110 97.3% 
 Categories  
Optimal dose of 
ACEI  
(n = 29)  
Suboptimal  dose of  
ACEI  









Frequency  % Frequency  % 
Table 3. 30 days post-discharge mortality 
Note; ACEI = angiotensin-converting enzyme inhibitor; HF = heart failure
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class improved more on the high dose group than on the low dose group 
(P=004). The benefit of survival was not different in both groups.12 
ATLAS study compared low dose lisinopril (2.5 to 5.0 mg daily) and 
high dose lisinopril (32.5 to 35 mg daily) on HF patients with NYHA 
functional class II to IV and an LVEF ≤30%. After minimum three years 
follow-up period, patients in the high-dose group revealed a nonsignifi-
cant 8% lower risk of mortality (p = 0.128) but a significant 12% lower 
risk of mortality or hospitalization for any cause (p = 0.002) and 24% 
lower risk hospitalizations for HF (p = 0.002) compared to the 
low-dose group.13 The fundamental differences between our study and 
those RCTs were: (1) the administration of optimal dose of ACEI was 
conducted during in-hospital treatment; (2) the follow-up period in our 
study was shorter than in those RCTs; and (3) we used three kinds of 
ACEI (captopril, ramipril, and lisinopril).    
 Our study had several limitations. First, the small number of 
patients and a short follow-up period might cause biased study results. 
Second, this study was a single-center study that might also cause 
biased study results. Third, we included all HF patients regardless of the 
LVEF. According to the previous studies, the benefit of ACEI in reducing 
mortality and rehospitalization was proven only in heart failure with 
reduced ejection fraction (HFrEF).13,24–26 Fourth, several factors are 
likely to be the confounders that might affect the study outcomes such 
as baseline hemodynamic profile, renal function, the presence of 
comorbidities, etiology of Hf, and also precipitating factors of HF. 
Multicenter research with (1) more specific and strict inclusion and 
exclusion criteria; (2) a large number of patients; and (3) longer 
follow-up duration is required.
5. Conclusion
 Our studies data suggested that the proportion of HF patients 
treated with optimal dose of ACEI during in-hospital setting were still 
low. The use of optimal dose of ACEI during in-hospital treatment 
reduced in-hospital mortality in HF patients.
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